Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study
Abstract Purpose There is a significant unmet need in treating patients with limited-stage small-cell lung cancer (LS-SCLC). The ETER701 study showed that Benmelstobart (TQB2450, an anti-PD-L1 antibody) combined with Anlotinib and chemotherapy achieved the longest progression-free survival (PFS) and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13885-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389906106777600 |
|---|---|
| author | Xiaoli Liu Xiaoyan Yin Lulu Zhuang Junxu Wen Zhonghui Wei Wenxing Cui Minghao Yu Kaikai Zhao Lanping Liu Lingling Kong Liyang Jiang Xuquan Jing Hui Zhu Xunqiang Wang Xinjun Dong Jinming Yu Xiangjiao Meng |
| author_facet | Xiaoli Liu Xiaoyan Yin Lulu Zhuang Junxu Wen Zhonghui Wei Wenxing Cui Minghao Yu Kaikai Zhao Lanping Liu Lingling Kong Liyang Jiang Xuquan Jing Hui Zhu Xunqiang Wang Xinjun Dong Jinming Yu Xiangjiao Meng |
| author_sort | Xiaoli Liu |
| collection | DOAJ |
| description | Abstract Purpose There is a significant unmet need in treating patients with limited-stage small-cell lung cancer (LS-SCLC). The ETER701 study showed that Benmelstobart (TQB2450, an anti-PD-L1 antibody) combined with Anlotinib and chemotherapy achieved the longest progression-free survival (PFS) and overall survival (OS) as a first-line therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). This suggests that TQB2450 and Anlotinib represent a promising treatment combination for LS-SCLC. This prospective study aimed to evaluate the efficacy and safety of TQB2450 combined with Anlotinib as maintenance therapy for LS-SCLC following concurrent or sequential chemoradiotherapy (CCRT or SCRT). Methods Patients who did not show disease progression after chemoradiotherapy were enrolled. They received TQB2450 and Anlotinib every 3 weeks for up to 24 months. TQB2450 was intravenously administered at a dose of 1200 mg every 3 weeks. Anlotinib was initiated at a dose of 8 mg daily for days 1–14; if well tolerated, the dose was increased to 10 mg. Adverse events (AEs) were recorded using electronic data capture system. The trial was registered at the ClinicalTrials.gov (NCT05942508, 06/07/2023). Results Fifteen patients were enrolled in the study between May 31, 2023 and October 13, 2023. As of October 31, 2024, the median follow-up time was 15.13 months. The 12-month PFS rate was 86.7% (95% CI, 71.1–100.0), and the OS rate at 12 months was 100%. The disease control rate was 100%. AEs were reported in 13 patients (86.67%), with fatigue being the most common treatment related AE (40.00%). And two SAEs were observed (elevation in cardiac troponin T and cerebral infarction), which were determined to be unlikely unrelated to the trial drugs. Radiation pneumonitis (RP) occurred in three patients, all classified as grade 2, and one patient developed grade 1 immune-related pneumonitis. No grade 5 AEs occurred, and no patients withdrew from the study due to AEs. Conclusions TQB2450 combined with Anlotinib showed promising efficacy and well tolerance in patients with LS-SCLC following first-line treatment. A randomized, double-blind, placebo-controlled Phase III clinical study (ClinicalTrials.gov Identifier: NCT06469879) is being conducted to further explore the efficacy and safety of TQB2450 combined with Anlotinib as maintenance therapy after definitive CCRT or SCRT for LS-SCLC. Trial registration ClinicalTrials.gov Identifier: NCT05942508. Date of registration: 7 June 2023. |
| format | Article |
| id | doaj-art-4bbc841f1053444dad5a147fb81630a7 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-4bbc841f1053444dad5a147fb81630a72025-08-20T03:41:49ZengBMCBMC Cancer1471-24072025-03-012511910.1186/s12885-025-13885-8Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib studyXiaoli Liu0Xiaoyan Yin1Lulu Zhuang2Junxu Wen3Zhonghui Wei4Wenxing Cui5Minghao Yu6Kaikai Zhao7Lanping Liu8Lingling Kong9Liyang Jiang10Xuquan Jing11Hui Zhu12Xunqiang Wang13Xinjun Dong14Jinming Yu15Xiangjiao Meng16Cheeloo College of Medicine, Shandong UniversityDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesCheeloo College of Medicine, Shandong UniversityDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesCheeloo College of Medicine, Shandong UniversityDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical SciencesChia Tai Tianqing Pharmarceutical Group Co., Ltd.Chia Tai Tianqing Pharmarceutical Group Co., Ltd.Cheeloo College of Medicine, Shandong UniversityCheeloo College of Medicine, Shandong UniversityAbstract Purpose There is a significant unmet need in treating patients with limited-stage small-cell lung cancer (LS-SCLC). The ETER701 study showed that Benmelstobart (TQB2450, an anti-PD-L1 antibody) combined with Anlotinib and chemotherapy achieved the longest progression-free survival (PFS) and overall survival (OS) as a first-line therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). This suggests that TQB2450 and Anlotinib represent a promising treatment combination for LS-SCLC. This prospective study aimed to evaluate the efficacy and safety of TQB2450 combined with Anlotinib as maintenance therapy for LS-SCLC following concurrent or sequential chemoradiotherapy (CCRT or SCRT). Methods Patients who did not show disease progression after chemoradiotherapy were enrolled. They received TQB2450 and Anlotinib every 3 weeks for up to 24 months. TQB2450 was intravenously administered at a dose of 1200 mg every 3 weeks. Anlotinib was initiated at a dose of 8 mg daily for days 1–14; if well tolerated, the dose was increased to 10 mg. Adverse events (AEs) were recorded using electronic data capture system. The trial was registered at the ClinicalTrials.gov (NCT05942508, 06/07/2023). Results Fifteen patients were enrolled in the study between May 31, 2023 and October 13, 2023. As of October 31, 2024, the median follow-up time was 15.13 months. The 12-month PFS rate was 86.7% (95% CI, 71.1–100.0), and the OS rate at 12 months was 100%. The disease control rate was 100%. AEs were reported in 13 patients (86.67%), with fatigue being the most common treatment related AE (40.00%). And two SAEs were observed (elevation in cardiac troponin T and cerebral infarction), which were determined to be unlikely unrelated to the trial drugs. Radiation pneumonitis (RP) occurred in three patients, all classified as grade 2, and one patient developed grade 1 immune-related pneumonitis. No grade 5 AEs occurred, and no patients withdrew from the study due to AEs. Conclusions TQB2450 combined with Anlotinib showed promising efficacy and well tolerance in patients with LS-SCLC following first-line treatment. A randomized, double-blind, placebo-controlled Phase III clinical study (ClinicalTrials.gov Identifier: NCT06469879) is being conducted to further explore the efficacy and safety of TQB2450 combined with Anlotinib as maintenance therapy after definitive CCRT or SCRT for LS-SCLC. Trial registration ClinicalTrials.gov Identifier: NCT05942508. Date of registration: 7 June 2023.https://doi.org/10.1186/s12885-025-13885-8Limited-stage small cell lung cancerCombined drug therapyAnlotinibTQB2450EfficacySafety |
| spellingShingle | Xiaoli Liu Xiaoyan Yin Lulu Zhuang Junxu Wen Zhonghui Wei Wenxing Cui Minghao Yu Kaikai Zhao Lanping Liu Lingling Kong Liyang Jiang Xuquan Jing Hui Zhu Xunqiang Wang Xinjun Dong Jinming Yu Xiangjiao Meng Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study BMC Cancer Limited-stage small cell lung cancer Combined drug therapy Anlotinib TQB2450 Efficacy Safety |
| title | Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study |
| title_full | Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study |
| title_fullStr | Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study |
| title_full_unstemmed | Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study |
| title_short | Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study |
| title_sort | efficacy and safety of tqb2450 combined with anlotinib as maintenance therapy for ls sclc after definitive concurrent or sequential chemoradiotherapy a prospective phase ib study |
| topic | Limited-stage small cell lung cancer Combined drug therapy Anlotinib TQB2450 Efficacy Safety |
| url | https://doi.org/10.1186/s12885-025-13885-8 |
| work_keys_str_mv | AT xiaoliliu efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT xiaoyanyin efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT luluzhuang efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT junxuwen efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT zhonghuiwei efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT wenxingcui efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT minghaoyu efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT kaikaizhao efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT lanpingliu efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT linglingkong efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT liyangjiang efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT xuquanjing efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT huizhu efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT xunqiangwang efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT xinjundong efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT jinmingyu efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy AT xiangjiaomeng efficacyandsafetyoftqb2450combinedwithanlotinibasmaintenancetherapyforlssclcafterdefinitiveconcurrentorsequentialchemoradiotherapyaprospectivephaseibstudy |